Literature DB >> 18245413

Risk factors for severe respiratory syncytial virus disease in children with cancer: the importance of lymphopenia and young age.

Chadi M El Saleeby1, Grant W Somes, John P DeVincenzo, Aditya H Gaur.   

Abstract

OBJECTIVE: We sought to determine the epidemiologic features of respiratory syncytial virus infection in immunocompromised pediatric patients and to identify the risk factors for severe disease.
METHODS: We designed a retrospective study examining the experience with respiratory syncytial virus infection in pediatric patients with underlying malignancies and hematopoietic stem cell transplant recipients seen between 1997 and 2005. Clinical and laboratory data were extracted from patient records, and independent predictors of disease severity were investigated.
RESULTS: Fifty-eight patients met the study criteria. Twenty-three patients (40%) had underlying diagnoses of acute lymphoblastic leukemia, 11 (19%) had solid tumors, and 24 (41%) were hematopoietic stem cell transplant recipients, had acute myeloid leukemia, or had severe combined immunodeficiency syndrome. Seventeen patients (29%) were < 2 years of age. Overall, 16 patients (28%) developed lower respiratory tract infections. The frequency of lower respiratory tract infections was highest in patients with hematopoietic stem cell transplants, acute myeloid leukemia, or severe combined immunodeficiency syndrome (42%). Independent predictors of lower respiratory tract infections were profound lymphopenia, with absolute lymphocyte counts of < 100 cells per mm3, and age of < or = 2 years. Of all patients with lower respiratory tract infections, 31% died as a result of respiratory syncytial virus infection. The overall mortality rate was low (5 of 58 patients; 8.6%). All deaths occurred in patients with lower respiratory tract infections who were before or after hematopoietic stem cell transplants or were < 2 years of age and receiving treatment for acute myeloid leukemia. Neutropenia was not a predictor of respiratory syncytial virus lower respiratory tract infection or death.
CONCLUSIONS: This study identified profound lymphopenia and young age as independent predictors of respiratory syncytial virus-related lower respiratory tract infections in immunocompromised children. No association between neutropenia and respiratory syncytial virus-related morbidity or death was found. These findings can guide interventions for respiratory syncytial virus infection in high risk hosts.

Entities:  

Mesh:

Year:  2008        PMID: 18245413     DOI: 10.1542/peds.2007-1102

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  29 in total

1.  Respiratory syncytial virus pathophysiology and affect of palivizumab in special populations: cystic fibrosis and immunosuppression.

Authors:  Michael E Speer
Journal:  J Pediatr Pharmacol Ther       Date:  2011-04

Review 2.  Respiratory viral infections in hematopoietic stem cell and solid organ transplant recipients.

Authors:  S Samuel Weigt; Aric L Gregson; Jane C Deng; Joseph P Lynch; John A Belperio
Journal:  Semin Respir Crit Care Med       Date:  2011-08-19       Impact factor: 3.119

Review 3.  Respiratory syncytial virus vaccine development.

Authors:  Julia L Hurwitz
Journal:  Expert Rev Vaccines       Date:  2011-10       Impact factor: 5.217

4.  Impact of respiratory viral panel testing on length of stay in pediatric cancer patients admitted with fever and neutropenia.

Authors:  Kaitlin Shinn; Martha Wetzel; Nicholas P DeGroote; Frank Keller; Michael Briones; James Felker; Sharon Castellino; Tamara P Miller
Journal:  Pediatr Blood Cancer       Date:  2020-09-02       Impact factor: 3.167

5.  Preventing hospitalizations for respiratory syncytial virus infection.

Authors:  Joan L Robinson; Nicole Le Saux
Journal:  Paediatr Child Health       Date:  2015 Aug-Sep       Impact factor: 2.253

6.  Human rhinovirus C infections in pediatric hematology and oncology patients.

Authors:  Carolina Loria; Jennifer A Domm; Natasha B Halasa; Elizabeth Heitman; E Kathryn Miller; Meng Xu; Benjamin R Saville; Haydar Frangoul; John V Williams
Journal:  Pediatr Transplant       Date:  2014-11-06

7.  Lymphopenia and treatment-related infectious complications in ANCA-associated vasculitis.

Authors:  Rémi Goupil; Soumeya Brachemi; Annie-Claire Nadeau-Fredette; Clément Déziel; Yves Troyanov; Valery Lavergne; Stéphan Troyanov
Journal:  Clin J Am Soc Nephrol       Date:  2012-12-06       Impact factor: 8.237

8.  Predictors of severity and mortality in children hospitalized with respiratory syncytial virus infection in a tropical region.

Authors:  Diego Andrés Rodríguez; Carlos E Rodríguez-Martínez; Andrea Constanza Cárdenas; Ivonne Emilce Quilaguy; Leydy Yasmin Mayorga; Luz Marlesvy Falla; Gustavo Nino
Journal:  Pediatr Pulmonol       Date:  2013-02-08

9.  Intranasal nanoemulsion-based inactivated respiratory syncytial virus vaccines protect against viral challenge in cotton rats.

Authors:  Jessica J O'Konek; Paul E Makidon; Jeffrey J Landers; Zhengyi Cao; Carrie-Anne Malinczak; Jessie Pannu; Jennifer Sun; Vira Bitko; Susan Ciotti; Tarek Hamouda; Zbigniew W Wojcinski; Nicholas W Lukacs; Ali Fattom; James R Baker
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

10.  Acute respiratory infections in children and adolescents with acute lymphoblastic leukemia.

Authors:  Hana Hakim; Ronald Dallas; Yinmei Zhou; Dequing Pei; Cheng Cheng; Patricia M Flynn; Ching-Hon Pui; Sima Jeha
Journal:  Cancer       Date:  2015-12-23       Impact factor: 6.860

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.